MetaVia (NASDAQ:MTVA – Free Report) had its price objective cut by Maxim Group from $6.00 to $3.00 in a research note published on Monday morning,Benzinga reports. They currently have a buy rating on the stock.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of MetaVia in a research report on Wednesday, April 16th.
Get Our Latest Stock Report on MTVA
MetaVia Stock Performance
MetaVia (NASDAQ:MTVA – Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.21. As a group, research analysts predict that MetaVia will post -3.9 earnings per share for the current year.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Read More
- Five stocks we like better than MetaVia
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- What Ray Dalio’s Latest Moves Tell Investors
- How to Read Stock Charts for Beginners
- Amazon: Why May Is the Last Month to Get the Stock at a Discount
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
